厄立特里亚药物警戒体系:关键策略、成功经验、挑战与启示
在低收入国家建立成熟药物警戒体系面临挑战,厄立特里亚在约9年内建成完备体系。2014—2019年该国年均向WHO全球个体病例安全性报告数据库提交646份/百万居民的报告,居非洲前列,并检出约30个安全信号、达到WHO快速基准评估成熟度三级,还通过药物警戒监测发现约55个不合格或伪造药品并被召回。
要点
- 厄立特里亚在约9年内建成完备药物警戒体系,年均报告646份/百万居民。
- 该国检出约30个安全信号,WHO快速基准评估达成熟度三级。
- 通过药物警戒监测发现约55个不合格或伪造药品并被召回。
核心结论
- 低收入国家厄立特里亚在约9年内建成完备药物警戒体系,报告量居非洲前列并取得多项可量化成果。
研究设计与样本
- 本文为描述性经验总结文章,介绍厄立特里亚药物警戒体系的成功经验、关键策略、挑战与启示。
主要发现
- 2014—2019年厄立特里亚药物警戒中心年均向WHO全球个体病例安全性报告数据库提交646份/百万居民的报告。
- 该中心检出约30个安全信号,并在WHO快速基准评估中达到成熟度三级。
- 通过药物警戒体系监测产品质量,发现约55个不合格或伪造药品,随后被国家药品与食品管理局从厄立特里亚市场召回。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Establishing a mature pharmacovigilance system in a low-income country is a challenge. Nevertheless, Eritrea, one such low-income country, was able to achieve a fully fledged pharmacovigilance system within a period of almost 9 years. In the last five years (2014-2019), the Eritrean Pharmacovigilance Centre has submitted, on average, 646 individual case safety reports (ICSRs) per million inhabitants per year to the World Health Organization (WHO) global database of ICSRs. As a result, Eritrea has been rated among the top reporting countries in Africa. The center has detected about 30 safety signals, achieved maturity level three on the WHO rapid benchmarking assessment, and gained huge political commitment. In the last few years, monitoring of product quality through the pharmacovigilance system found approximately 55 medical products that were either substandard or falsified and were subsequently recalled from the Eritrean market by the National Medicines and Food Administration. The aim of this article is to describe Eritrea's success stories, key strategies for success, challenges encountered, and lessons learned to share them with the international pharmacovigilance community and beyond.
引用
- Russom M, Bahta I, Debesai M, et al. Eritrean Pharmacovigilance System: Key Strategies, Success Stories, Challenges and Lessons Learned. Drug Saf. 2021. PMID: 34472048. doi:10.1007/s40264-021-01102-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。